MTRAC sitagliptin review updated
The Midlands Therapeutic Review and Advisory Committee has published an updated review of sitagliptin (Januvia®).
This review places sitagliptin as having a lower place in therapy but supported by stronger evidence. In combination with other hypoglycaemic drugs it has been shown to lower HbA1c to a greater extent than placebo and has been shown to be non-inferior to glipizide.
MTRAC recommends that, "sitagliptin is suitable for prescribing in primary care upon the advice of a specialist or a GP with a special interest in diabetes". This update notes that sitagliptin can now be used, within license, in combination with metformin and a sulphonylurea for patients who fail to achieve adequate glycaemic control.
Action: Clinicians should be aware of the licence extension for sitagliptin. This drug is still new to the market and should be used cautiously; any suspected adverse drug reactions should be reported through the YellowCard system.
« CMO Update 47 | Varenicline and serious neuropsychiatric symptoms » |
[...] places sitagliptin as having a lower place in therapy but supported by stronger evidence. It was previously known that in combination with other hypoglycaemic drugs it has been shown to lower HbA1c to a greater [...]
Pingback by Prescribing Advice for GPs » MTRAC sitagliptin review updated — April 23, 2010 #